Safety evaluation
treatment-emergent adverse events, deaths, TEAEs
ADVERSE EVENTS
Overall, 67 cases of treatment-emergent adverse events (TEAEs) were observed in 49.1% (27 of 55) of the subjects receiving contezolid acefosamil, specifically in 14 (38.9%) of the 36 subjects receiving IV administration of contezolid acefosamil and 13 (68.4%) of the 19 subjects taking contezolid acefosamil orally.A total of 29 cases of drug-related adverse events (AEs) were reported, specifically, in 4 (11.1%) of 36 subjects after receiving contezolid acefosamil intravenously and 9 (47.4%) of 19 subjects receiving oral contezolid acefosamil (1 subject in the single-dose cohorts and 8 subjects in the multiple-dose cohort) (Summary of drug-related TEAEs after intravenous and oral administration of contezolid acefosamil in healthy Chinese subjectsData are presented as number (%) unless otherwise specified. All of the TEAEs in this study were mild in severity and resolved spontaneously without treatment. No deaths, other serious adverse events (SAEs), significant AEs, or other AEs leading to early withdrawal from this trial were reported. No concomitant medication or treatment was used.